Department of Biological and Environmental Sciences, California University of PA, California, PA 15301, USA.
In Vivo. 2012 Jul-Aug;26(4):549-52.
BACKGROUND/AIM: Our earlier studies on ovarian tumor xenografts provide evidence that co-treatment with selenite prevents the development of resistance to single-treatment using the drug cisplatin. However, these studies did not reflect the repetitive schedule of clinical chemotherapy. We hypothesized that selenite can enhance the effectiveness of cisplatin during the course of repeated treatments, reflecting clinical practices.
Multiple i.p. injections of cisplatin (5.2 mg/kg) alone, or with selenite (1.5 mg/kg), were administered to mice bearing subcutaneous xenografts of human ovarian tumor (A2780) cells and the tumor volume was recorded.
Selenite increased and prolonged the efficacy of multiple cisplatin treatments, although selenite was not an effective inhibitor by itself. In the absence of selenite, the effectiveness of cisplatin decreased.
The ability of selenite to prolong the effectiveness of repetitive cisplatin treatment, most likely by preventing the development of resistance, makes it a strong candidate for inclusion in clinical trials.
背景/目的：我们之前关于卵巢肿瘤异种移植的研究提供了证据，表明亚硒酸盐联合治疗可预防单用药物顺铂治疗产生耐药性。然而，这些研究并没有反映出临床化疗的重复方案。我们假设亚硒酸盐可以增强顺铂在重复治疗过程中的效果，反映临床实践。
用顺铂（5.2mg/kg）单独或联合亚硒酸盐（1.5mg/kg）对皮下移植有人卵巢肿瘤（A2780）细胞的小鼠进行多次腹腔注射，并记录肿瘤体积。
亚硒酸盐增加并延长了多次顺铂治疗的效果，尽管亚硒酸盐本身并不是一种有效的抑制剂。没有亚硒酸盐时，顺铂的疗效下降。
亚硒酸盐延长重复顺铂治疗效果的能力，很可能是通过防止耐药性的发展，使其成为临床试验的有力候选药物。
